Related Experiment Video
Updated: Oct 2, 2025
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.4K
Heptamethine Cyanine-Based Application for Cancer Theranostics
Lei Zhang1, Hang Jia2, Xuqian Liu2
1School of Basic Medical Sciences, Laboratory for Nanomedicine, Henan University, Kaifeng, China.
Frontiers in Pharmacology
|February 28, 2022
Summary
Heptamethine cyanine (Cy7) shows promise for cancer theranostics, enabling simultaneous tumor imaging and treatment. This review explores Cy7
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Cancer remains a leading cause of mortality worldwide.
- Personalized cancer treatments require agents with tumor-targeting and imaging capabilities.
- Heptamethine cyanine (Cy7) exhibits favorable properties for cancer theranostics.
Purpose of the Study:
- To comprehensively review the applications of Cy7 and its derivatives in cancer.
- To highlight Cy7's potential in near-infrared fluorescence (NIRF) imaging, photothermal therapy (PTT), and photodynamic therapy (PDT).
- To explore Cy7-based nanoprobes for multimodal imaging and combination therapy.
Main Methods:
- Literature review of Cy7 applications in cancer research.
- Analysis of Cy7's optical properties and tumor-targeting capacity.
- Examination of Cy7's role in nanomedicine for cancer theranostics.
Main Results:
- Cy7 demonstrates excellent tumor-targeting efficacy and imaging potential.
- Cy7 facilitates non-invasive detection and treatment of tumors.
- Cy7-based nanoprobes enable simultaneous multimodal imaging and combination therapy.
Conclusions:
- Cy7 is a versatile agent for advanced cancer theranostics.
- Further development of Cy7-based strategies may lead to improved cancer therapies.
- Cy7 holds potential for clinical translation in cancer management.
